FiercePharma with assistance from EvaluatePharma, have assembled a list of the top 10 most-anticipated new drug launches of 2020 based on estimated global sales in 2024. Eight out of the ten could break the blockbuster barrier in four short year putting a new batch of heavy hitters in pharma’s ranks. First is AstraZeneca and Daiichi Sankyo’s breast
Johnson & Johnson’s Invokana has become the only drug in the SGLT2 inhibitor class to be approved by the FDA for treating diabetic kidney disease (DKD) and to reduce the risk of hospitalisation for heart failure in patients with type 2 diabetes and DKD. Based on results of the CREDENCE trial, J&J’s drug reduced the
In the 1980s, only 4% of new drugs approved by the FDA were cancer treatments. But since 2010, cancer drugs have claimed 27% of new approvals—a share that doubled over the previous decade—according to a new report from the Tufts Center for the Study of Drug Development. It is believed that this is due to
President Donald Trump is preparing an executive order outlining a “favoured nations clause”, where US prices will reflect those in the country paying the least for their medicines. Trump recently made the announcement in a press briefing outside the White House, more than two years after promises to tackle high drug prices had been a
